|  |  |
| --- | --- |
| papers x student seminar AA 2021-22 | |
| manipulation of the genome integration profile of retroviral vectors | **Modlich U**, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, Bueren J, Baum C. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther**. 2009** Nov;17(11):1919-28. doi: 10.1038/mt.2009.179. Epub 2009 Aug 11. PMID: 19672245; PMCID: PMC2835038. |
| **Montini E**, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C, Di Serio C, von Kalle C, Naldini L. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009 Apr;119(4):964-75. doi: 10.1172/JCI37630. Epub **2009** Mar 23. PMID: 19307726; PMCID: PMC2662564. |
| **Bona R**, Michelini Z, Mazzei C, Gallinaro A, Canitano A, Borghi M, Vescio MF, Di Virgilio A, Pirillo MF, Klotman ME, Negri D, Cara A. Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. Mol Ther Methods Clin Dev. **2021** Oct 1;23:263-275. doi: 10.1016/j.omtm.2021.09.011. PMID: 34729374; PMCID: PMC8526422. |
| **Biffi A**, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, Cesani M, Benedicenti F, Plati T, Rubagotti E, Merella S, Capotondo A, Sgualdino J, Zanetti G, von Kalle C, Schmidt M, Naldini L, Montini E. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood. **2011** May 19;117(20):5332-9. doi: 10.1182/blood-2010-09-306761. Epub 2011 Mar 14. PMID: 21403130. |
| improving lentiviral transduction | **Petrillo** C, Thorne LG, Unali G, Schiroli G, Giordano AMS, Piras F, Cuccovillo I, Petit SJ, Ahsan F, Noursadeghi M, Clare S, Genovese P, Gentner B, Naldini L, Towers GJ, Kajaste-Rudnitski A. Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell Stem Cell. **2018** Dec 6;23(6):820-832.e9. doi: 10.1016/j.stem.2018.10.008. Epub 2018 Nov 8. PMID: 30416070; PMCID: PMC6292841. |
| **Heffner** GC, Bonner M, Christiansen L, Pierciey FJ, Campbell D, Smurnyy Y, Zhang W, Hamel A, Shaw S, Lewis G, Goss KA, Garijo O, Torbett BE, Horton H, Finer MH, Gregory PD, Veres G. Prostaglandin E2 Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells. Mol Ther. 2018 Jan 3;26(1):320-328. doi: 10.1016/j.ymthe.2017.09.025. Epub **2017** Oct 5. PMID: 29102562; PMCID: PMC5763075. |
| efficient gene transfer and HSC engraftment and long-term repopulation capacity | **Piras** F, Riba M, Petrillo C, Lazarevic D, Cuccovillo I, Bartolaccini S, Stupka E, Gentner B, Cittaro D, Naldini L, Kajaste-Rudnitski A. Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. EMBO Mol Med. **2017** Sep;9(9):1198-1211. doi: 10.15252/emmm.201707922. PMID: 28667090; PMCID: PMC5582409. |
| nvestigating novel administra- tion routes | **Marktel** S, Scaramuzza S, Cicalese MP, Giglio F, Galimberti S, Lidonnici MR, Calbi V, Assanelli A, Bernardo ME, Rossi C, Calabria A, Milani R, Gattillo S, Benedicenti F, Spinozzi G, Aprile A, Bergami A, Casiraghi M, Consiglieri G, Masera N, D'Angelo E, Mirra N, Origa R, Tartaglione I, Perrotta S, Winter R, Coppola M, Viarengo G, Santoleri L, Graziadei G, Gabaldo M, Valsecchi MG, Montini E, Naldini L, Cappellini MD, Ciceri F, Aiuti A, Ferrari G. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med. **2019** Feb;25(2):234-241. doi: 10.1038/s41591-018-0301-6. Epub 2019 Jan 21. PMID: 30664781. |
| immune response to the therapeutic gene and to the transduced cells, | **Milani** M, Annoni A, Bartolaccini S, Biffi M, Russo F, Di Tomaso T, Raimondi A, Lengler J, Holmes MC, Scheiflinger F, Lombardo A, Cantore A, Naldini L. Genome editing for scalable production of alloantigen-free lentiviral vectors for *in vivo* gene therapy. EMBO Mol Med. **2017** Nov;9(11):1558-1573. doi: 10.15252/emmm.201708148. PMID: 28835507; PMCID: PMC5666310. |
| targeted genome editing | **Schiroli G**, Ferrari S, Conway A, Jacob A, Capo V, Albano L, Plati T, Castiello MC, Sanvito F, Gennery AR, Bovolenta C, Palchaudhuri R, Scadden DT, Holmes MC, Villa A, Sitia G, Lombardo A, Genovese P, Naldini L. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci Transl Med. **2017** Oct 11;9(411):eaan0820. doi: 10.1126/scitranslmed.aan0820. PMID: 29021165. |
| increase the yield of edited cells, | **Schiroli G**, Conti A, Ferrari S, Della Volpe L, Jacob A, Albano L, Beretta S, Calabria A, Vavassori V, Gasparini P, Salataj E, Ndiaye-Lobry D, Brombin C, Chaumeil J, Montini E, Merelli I, Genovese P, Naldini L, Di Micco R. Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. Cell Stem Cell. **2019** Apr 4;24(4):551-565.e8. doi: 10.1016/j.stem.2019.02.019. Epub 2019 Mar 21. PMID: 30905619; PMCID: PMC6458988. |
| modulation of antiviral proteins in host cells | **Sertkaya H,** Hidalgo L, Ficarelli M, Kmiec D, Signell AW, Ali S, Parker H, Wilson H, Neil SJD, Malim MH, Vink CA, Swanson CM. Minimal impact of ZAP on lentiviral vector production and transduction efficiency. Mol Ther Methods Clin Dev. **2021** Aug 28;23:147-157. doi: 10.1016/j.omtm.2021.08.008. PMID: 34703838; PMCID: PMC8517000. |
| improving expression of transposon-mediated integrated gene | **Skipper** KA, Hollensen AK, Antoniou MN, Mikkelsen JG. Sustained transgene expression from sleeping beauty DNA transposons containing a core fragment of the HNRPA2B1-CBX3 ubiquitous chromatin opening element (UCOE). BMC Biotechnol. **2019** Nov 9;19(1):75. doi: 10.1186/s12896-019-0570-2. PMID: 31706316; PMCID: PMC6842454. |
| gene therapy patents | **Zhou** W, Wang X. Human gene therapy: A patent analysis. Gene. 2021 Nov 30;803:145889. doi: 10.1016/j.gene.2021.145889. Epub **2021** Aug 8. PMID: 34371094. |
| retargeting LV vectors to specific cells | **Panigaj** M, Marino MP, Reiser J. Tagging and Capturing of Lentiviral Vectors Using Short RNAs. Int J Mol Sci. **2021** Sep 23;22(19):10263. doi: 10.3390/ijms221910263. PMID: 34638603; PMCID: PMC8508951. |
| X-linked SCID therapeutic effects | **Clarke** EL, Connell AJ, Six E, Kadry NA, Abbas AA, Hwang Y, Everett JK, Hofstaedter CE, Marsh R, Armant M, Kelsen J, Notarangelo LD, Collman RG, Hacein-Bey-Abina S, Kohn DB, Cavazzana M, Fischer A, Williams DA, Pai SY, Bushman FD. T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med. **2018** Sep 28;10(1):70. doi: 10.1186/s13073-018-0580-z. PMID: 30261899; PMCID: PMC6161392. |
| Foamy virus based vectors | **Humbert** O, Chan F, Rajawat YS, Torgerson TR, Burtner CR, Hubbard NW, Humphrys D, Norgaard ZK, O'Donnell P, Adair JE, Trobridge GD, Scharenberg AM, Felsburg PJ, Rawlings DJ, Kiem HP. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy. Blood Adv. **2018** May 8;2(9):987-999. doi: 10.1182/bloodadvances.2018016451. PMID: 29720491; PMCID: PMC5942001. |
| **Trobridge** GD. Foamy virus vectors for gene transfer. Expert Opin Biol Ther. **2009** Nov;9(11):1427-36. doi: 10.1517/14712590903246388. PMID: 19743892; PMCID: PMC2782412. |
| targeting CD8 cells | **Michels** A, Frank AM, Günther DM, Mataei M, Börner K, Grimm D, Hartmann J, Buchholz CJ. Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. Mol Ther Methods Clin Dev. **2021** Oct 1;23:334-347. doi: 10.1016/j.omtm.2021.09.014. PMID: 34729380; PMCID: PMC8531454. |
| lentiviral vectors production, bioproducts operations | **Perry** C, Rayat ACME. Lentiviral Vector Bioprocessing. Viruses. **2021** Feb 9;13(2):268. doi: 10.3390/v13020268. PMID: 33572347; PMCID: PMC7916122. |
| ADA2 gene therapy | **Zoccolillo** M, Brigida I, Barzaghi F, Scala S, Hernández RJ, Basso-Ricci L, Colantuoni M, Pettinato E, Sergi LS, Milardi G, Capasso P, Lombardo A, Gregori S, Sanvito F, Schena F, Cesaro S, Conti F, Pession A, Benedetti F, Gattorno M, Lee PY, Naldini L, Cicalese MP, Aiuti A, Mortellaro A. Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. Blood Adv. **2021** Aug 24;5(16):3174-3187. doi: 10.1182/bloodadvances.2020003811. PMID: 34424322; PMCID: PMC8405196. |
|  |  |